June 2026 – QIAGEN Expands QIAcuity Digital PCR Gene Expression PortfolioQIAGEN expanded its QIAcuity digital PCR portfolio by launching new gene expression assays and kits designed to accelerate digital PCR adoption in research and biopharmaceutical applications, enhancing sensitivity and workflow efficiency.
May 2026 – QIAGEN Launches AI-Powered QIA Agent for Molecular Testing WorkflowsQIAGEN introduced QIA Agent, an AI-powered scientific assistant that supports researchers across sample preparation, PCR kit selection, assay optimization, and molecular biology workflows, improving laboratory productivity and decision-making.
March 2026 – Thermo Fisher Scientific Expands PCR Reagent and Molecular Diagnostics PortfolioThermo Fisher Scientific continued expanding its PCR kit and molecular diagnostics portfolio by introducing advanced PCR reagents and automation solutions to improve clinical diagnostics, infectious disease testing, and life science research workflows.
January 2026 – QIAGEN Strengthens PCR and Sample Technology Business Through Parse Biosciences IntegrationFollowing the completion of its Parse Biosciences acquisition in late 2025, QIAGEN expanded its sample technologies portfolio with new workflow solutions supporting PCR-based research, genomics, and single-cell analysis, strengthening its molecular biology product offering.